Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Rhea-AI Summary
Outlook Therapeutics (Nasdaq: OTLK) announced that the FDA’s Office of New Drugs has granted its appeal in the Formal Dispute Resolution process for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for neovascular age-related macular degeneration (nAMD).
The FDA concluded that substantial evidence of effectiveness has been established based on NORSE TWO plus confirmatory data, enabling Outlook Therapeutics to plan a Class 1 BLA resubmission in June 2026, with a PDUFA decision expected within 60 days of FDA receipt. If approved, ONS-5010/LYTENAVA™ would be the first FDA-approved ophthalmic bevacizumab formulation.
Positive
- FDA grants appeal in Formal Dispute Resolution for ONS-5010/LYTENAVA™
- OND concludes substantial evidence of effectiveness for LYTENAVA™ in nAMD
- Company plans Class 1 BLA resubmission in June 2026
- PDUFA decision expected within 60 days of BLA resubmission receipt
- If approved, product could be first FDA-approved ophthalmic bevacizumab
Negative
- Product previously received a Complete Response Letter on December 30, 2025
- Regulatory approval for ONS-5010/LYTENAVA™ in the US is still pending
- Final labeling must still be agreed with FDA Division and OSM
News Market Reaction – OTLK
In the May 26 session, OTLK gained 29.14%, reflecting a significant positive market reaction. Argus tracked a peak move of +86.0% during that session. Argus tracked a trough of -7.0% from its starting point during tracking. Our momentum scanner triggered 82 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 6.9x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | Quarterly earnings update | Neutral | +0.5% | Reported Q2 FY2026 results with sharply lower GAAP loss but wider adjusted loss. |
| Apr 23 | Equity offering closed | Negative | +9.8% | Closed $5.0M registered direct offering with matching warrants at $0.31 per share. |
| Apr 22 | Equity offering announced | Negative | -7.4% | Announced $5.0M registered direct offering and concurrent private-placement warrants. |
| Apr 21 | FDR meeting completed | Neutral | -13.7% | Completed FDA Federal Dispute Resolution meeting; formal response expected in May 2026. |
| Apr 07 | FDR request accepted | Positive | +6.2% | FDA accepted Formal Dispute Resolution Request for ONS-5010/LYTENAVA after CRL. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
OTLK has shown mixed reactions around financings and regulatory steps, with one offering drawing a positive move but another selling off, while most regulatory updates and earnings saw modestly positive or contained reactions.
Over the past few months, Outlook Therapeutics has focused on advancing ONS-5010/LYTENAVA™. In April 2026, the company initiated and completed key FDA dispute‑resolution steps, with prior news on the FDR request and meeting producing share moves between about -13.68% and +6.18%. Two $5.0 million registered direct/ATM‑related offerings in late April triggered opposite market reactions. The mid‑May Q2 FY2026 update highlighted reduced net loss and low cash levels. Today’s appeal win and planned June 2026 BLA resubmission build directly on this regulatory sequence.
Key Terms
biologics license application regulatory
complete response letter regulatory
formal dispute resolution regulatory
pdufa date regulatory
bevacizumab medical
pharmacovigilance medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company plans to resubmit BLA to the FDA in June 2026
ISELIN, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the appeal following completion of the Formal Dispute Resolution (FDR) process with the Office of New Drugs (OND). The FDA concluded that substantial evidence of effectiveness has been established for LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD). As a result, Outlook Therapeutics expects to resubmit the ONS-5010/LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) in June 2026.
The Company engaged in the FDR process after its recent Type A meeting with the Division of Ophthalmology (Division) and Office of Specialty Medicine (OSM) related to the December 30, 2025 Complete Response Letter (CRL) for the BLA for ONS-5010/LYTENAVA™.
In its formal response, OND determined that the results of the NORSE TWO trial, together with confirmatory evidence including NORSE EIGHT, natural history, and mechanistic and pharmacodynamic data, establish substantial evidence of effectiveness for LYTENAVA™ for the treatment of nAMD. The response directs the Division and OSM to work with Outlook Therapeutics to reach an agreement on final labeling. As indicated in the formal decision, it is anticipated that this will be a Class 1 resubmission with a PDUFA date and decision expected within 60 days of FDA’s receipt of the resubmission.
“We appreciate the opportunity to engage with the FDA through the FDR process,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “The Agency’s action on our appeal provides a clear path forward toward U.S. approval.”
Mr. Jahr added, “Importantly, we are extremely grateful for the continued support and confidence of our stakeholders throughout this process. I would especially like to thank our team for their tireless efforts, resilience and unwavering commitment throughout what was a rigorous and highly demanding process. Their persistence and professionalism were instrumental in achieving this successful outcome. We have remained resolute that patients deserve additional FDA-approved options for the treatment of nAMD and look forward to receiving an approval decision for ONS-5010/LYTENAVA™.”
If approved, ONS-5010/LYTENAVA™ would be the first FDA-approved ophthalmic formulation of bevacizumab supported by an FDA-approved manufacturing process, FDA-approved labeling, as well as robust pharmacovigilance.
About ONS-5010 / LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)
ONS-5010/LYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the United States for the treatment of wet AMD. LYTENAVA™ (bevacizumab gamma) is the subject of a centralized Marketing Authorization granted by the European Commission in the EU and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD. In certain European Union Member States, ONS-5010/LYTENAVA™ must receive pricing and reimbursement approval before it can be sold.
In the United States, ONS-5010/LYTENAVA ™ (bevacizumab-vikg) is investigational. If approved, it has the potential to be the first ophthalmic formulation of bevacizumab-vikg approved by the FDA for use in ophthalmology.
Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection, the binding of bevacizumab to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Forward-Looking Statements
This press release contains statements that may or are considered “forward-looking statements”. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “look forward,” “may,” “on track,” “plan,” “potential,” “target,” “will,” or “would”, the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, plans to resubmit the BLA for ONS-5010 and the timing thereof, plans for continued engagement with the FDA, the potential of ONS-5010/LYTENAVA™ as a treatment for wet AMD, the potential for ONS-5010 to receive approval from the FDA and the timing thereof, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the SEC on December 19, 2025, as supplemented by the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 and future reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of global geopolitical conflict, tariffs and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
